title: [Effect of Xinfeng Capsule on Lipoprotein Metabolism of Rheumatoid Arthritis Patients].
abstract: OBJECTIVE
  To explore the effect of Xinfeng Capsule (XC) on lipoprotein metabolism of rheumatoid arthritis (RA) patients.
  
  
  METHODS
  Totally 180 RA patients were assigned to the experimental group and the control group by random digit table, 90 in each group. Patients in the experimental group took XC (three pills each time, three times daily), while those in the control group took Methotrexate Tablet (four tablets each time, once per week). One month consisted of one therapeutic course and all patients were treated for two therapeutic courses. A healthy control group consisting of 60 patients was also set up. Changes of lipoprotein indices, clinical efficacy, lipid metabolism, joint symptoms and signs, activity indicators were observed, and correlation analyses were performed.
  
  
  RESULTS
  Compared with the healthy control group, expression levels of prealbumin (PA), globulin (GLO), high-density lipoprotein (HDL), apolipoprotein Al (Apo-A1) were lowered in RA patients (P <0. 05, P <0. 01). Correlation analyses showed that PA was negatively correlated with joint tenderness, morning stiffness time, disease activity score (DAS-28), C-reactive protein (CRP), interleukin (IL)-6, respectively. Total protein (TP) was negatively correlated with joint tenderness. GLO was negatively correlated with joint tenderness and DAS-28. HDL was negatively correlated with erythrocyte sedimentation rate (ESR) and endothelin (ET)-1. Apo-Al was negatively correlated with joint pain; Apo-B was negatively correlated with CRP; LDL was negatively correlated with morning stiffness time (P <0. 05, P <0. 01). Compared with before treatment, expression levels of PA, HDL, Apo-A1 , Apo-B, and serum IL-10 contents increased, and expression levels of ESR, CRP, IL-6, ET-1 , joint pain, joint swelling, morning stiffness time, and DAS-28 decreased in the experimental group (P <0. 05, P <0. 01). PA increased more after treatment than before treatment in the control group (P <0. 01). There was statistical difference in joint symptoms (except joint tenderness) and activity indices (except ET-1) in the control group (P <0. 05, P <0. 01). Compared with the control group after treatment, PA and HDL increased, ET-1 and duration of morning stiffness decreased in the experimental group (all P <0. 05).
  
  
  CONCLUSIONS
  Lipoprotein metabolic disorder exists in RA patients, and it is associated with disease activity. XC could obviously improve lipoprotein metabolism and joint symptoms.
authors.forename: Jian
authors.initials: J
authors.lastname: Liu
authors.forename: Lei
authors.initials: L
authors.lastname: Wan
authors.forename: Chuan-bing
authors.initials: CB
authors.lastname: Huang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Wang
authors.forename: Yu-zhen
authors.initials: YZ
authors.lastname: Pan
authors.forename: Xiu-li
authors.initials: XL
authors.lastname: Xie
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism*; D001799:Blood Sedimentation; D002097:C-Reactive Protein; D002214:Capsules; D004365:Drugs, Chinese Herbal / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D016753:Interleukin-10; D015850:Interleukin-6; D008074:Lipoproteins; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008727:Methotrexate
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; C508609:IL10 protein, human; C508600:IL6 protein, human; D015850:Interleukin-6; D008074:Lipoproteins; D008075:Lipoproteins, HDL; C533622:xinfeng; D016753:Interleukin-10; D002097:C-Reactive Protein; D008727:Methotrexate